Hims & Hers Health

HIMS

Market cap $12.5B

Overview Fund Activity

55.50 USD

+3.74

7.23%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

55.00

-0.50

0.9%

1 day

7.23%

5 days

12.99%

1 month

15.72%

3 months

-2.89%

6 months

63.57%

Year to date

120.24%

1 year

250.82%

5 years

404.55%

10 years

466.33%

About: Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, haircare and more.

Employees: 1,637

Consumer Staples Household & Personal Products

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

156% more first-time investments, than exits

New positions opened: 138 | Existing positions closed: 54

88% more capital invested

Capital invested by funds: $4.63B [Q1] → $8.72B (+$4.09B) [Q2]

33% more repeat investments, than reductions

Existing positions increased: 183 | Existing positions reduced: 138

18% more funds holding

Funds holding: 420 [Q1] → 496 (+76) [Q2]

7.98% more ownership

Funds ownership: 73.23% [Q1] → 81.21% (+7.98%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 9 [Q1] → 9 (+0) [Q2]

31% less call options, than puts

Call options by funds: $1.31B | Put options by funds: $1.91B

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$37

-33% downside

Avg. target

$53

-5% downside

High target

$68

23% upside

2 analyst ratings

1 positive

50%

1 neutral

50%

0 negative

0%

Canaccord Genuity Maria Ripps	$68	Buy Maintained	12 Sep 2025
Truist Securities Jailendra Singh	$37	Hold Maintained	18 Aug 2025

See Analyst Rankings

Financial journalist opinion

Based on 93 articles about HIMS published over the past 30 days

US FDA chief says Super Bowl ad by Hims & Hers 'breached' drug promotion rules

U.S. Food and Drug Administration Commissioner Martin Makary said on Friday that Hims & Hers' Super Bowl advertisement breached federal law as it highlighted the benefits of weight-loss drugs without mentioning side effects.

US FDA chief says Super Bowl ad by Hims & Hers 'breached' drug promotion rules

Zacks Investment Research

Hims & Hers Surges 64.1% in 6 Months: How to Play the Stock?

HIMS accelerates with new men's health launches, global expansion plans and strong subscriber-driven growth, but rising costs strain gross margins.

Hims & Hers Surges 64.1% in 6 Months: How to Play the Stock?

Hims & Hers Looks Like Hyper Growth At A Reasonable Price

Hims is now a GARP stock, combining rapid revenue and subscriber growth with a lower, fair valuation after a recent selloff. The company's scalable model, product launches, and global expansion plans support management's ambitious 2030 revenue and EBITDA targets. The stock trades at a reasonable historical and forward-looking valuation. A potential interim bottom and a near-term rebound are both supported by technical analysis.

Hims & Hers Looks Like Hyper Growth At A Reasonable Price

Marius Pharmaceuticals and Hims & Hers™ Collaborate to Expand Access to KYZATREX® (testosterone undecanoate) CIII Capsules, the First FDA-Approved Oral Testosterone Therapy Offered on the Hims & Hers Platform

RALEIGH, N.C., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, Inc. today announced a collaboration with Hims & Hers™, one of the largest digital health platforms for men, to make KYZATREX® , an FDA-approved oral testosterone replacement therapy for adult men with low or no testosterone levels due to certain medical conditions, available to patients through the Hims & Hers platform in the coming months. This marks the first time Hims & Hers will offer an FDA-approved oral testosterone therapy, underscoring KYZATREX's position as a leader in the testosterone therapy space.

Marius Pharmaceuticals and Hims & Hers™ Collaborate to Expand Access to KYZATREX® (testosterone undecanoate) CIII Capsules, the First FDA-Approved Oral Testosterone Therapy Offered on the Hims & Hers Platform

Investors Business Daily

Hims & Hers Stock Jumps On Long-Awaited Foray Into Testosterone

Hims stock popped Wednesday after the telemedicine giant announced its long-awaited foray into offering testosterone replacement therapy.

Hims & Hers Stock Jumps On Long-Awaited Foray Into Testosterone

Hims & Hers Bets On Hormonal Health To Revive Investor Confidence

Hims & Hers Health Inc. HIMS launched a new category in men's health on Wednesday, offering access to affordable and personalized treatment plans for low testosterone.

Hims & Hers Bets On Hormonal Health To Revive Investor Confidence

Hims & Hers: The Next Chapter For Investors

Revenue is scaling rapidly, from $150M in 2020 to ~$2.3B expected in 2025. Over 90% of revenue is recurring subscriptions, ensuring stability and visibility. The vertically integrated model builds a brand moat and delivers 76% gross margins.

Hims & Hers: The Next Chapter For Investors

Hims & Hers launches treatment plans for low testosterone

Hims & Hers Health said on Wednesday it is launching a new category in men's health, offering access to personalized treatment plans for low testosterone.

Hims & Hers launches treatment plans for low testosterone

Hims Launches New Category in Men's Health with Exclusive Branded Oral Testosterone and Expanded Personalized Treatments

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the launch of a new category in men's health, offering access to innovative, affordable, and personalized treatment plans for low testosterone. An estimated twenty million men in the U.S. struggle with low testosterone1 2. Left untreated, it can drain energy, dull mood and sexual desire, and raise risks of heart disease, diabetes, and cancer. Treatment can restore.

Hims Launches New Category in Men's Health with Exclusive Branded Oral Testosterone and Expanded Personalized Treatments

Hims & Hers Health Expands Testosterone Offerings

Hims & Hers Health is launching treatments for low testosterone on its telehealth platform, venturing deeper into a category often marred by stigma, according to its chief executive.

Hims & Hers Health Expands Testosterone Offerings

See News Rankings

Charts implemented using Lightweight Charts™